๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
NCT06176027Relapsed Peripheral T-Cell Lymphomas, Refractory Peripheral T-Cell Lymphomas
DrugAzacytidine
Navy General Hospital, Beijing
Phase 1/2
52
Beijing
2024-10-01
Recruiting
Multitarget Stereotactic Electrophysiological Recording and Stimulation for Tourette Syndrome
NCT06889480Tourette Syndrome, Deep Brain Stimulation
Beijing Tiantan Hospital
Not applicable
5
Beijing
2024-10-01
Not yet open
All-cause and Diseases-specific Mortality of High-risk HPV Infection
NCT06631495HPV Infection
Peking Union Medical College Hospital
Observational
100,000
Beijing
2024-10-01
Recruiting
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
NCT06622031Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
DrugLenvatinib
Sun Yat-sen University
Not applicable
42
Beijing
2024-10-01
Not yet open
Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence
NCT06558019Ovarian Cancer
Lei Li
Observational
509
Beijing
2024-10-01
Recruiting
Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning
NCT06754670Mechanical Ventilation, Weaning Failure, Hypophosphatemia
Peking Union Medical College
Observational
70
Beijing
2024-10-01
Recruiting
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
NCT06609876Hepatocellular Carcinoma, Microwave Ablation, Donafenib, Recurrent Tumor
DrugDonafenib
Sun Yat-sen University
Not applicable
108
Beijing
2024-10-01
By invitation
Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome
NCT06660329Blau Syndrome
Peking Union Medical College Hospital
Phase 4
30
Beijing
2024-10-01
Recruiting
Transaxillary TAVR With Solely Echocardiography Guidance
NCT07035847Aortic Stenosis
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
20
Beijing
2024-10-01
Recruiting
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
NCT06609850Recurrent Hepatocellular Carcinoma, Lenvatinib, Local Therapy, Ablation
DrugLenvatinb
Sun Yat-sen University
Not applicable
116
Beijing
2024-10-01
Recruiting
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
NCT06581081Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
Peking University People's Hospital
Not applicable
130
Beijing
2024-10-01
Recruiting
Application of Non-inductive Intelligent Physical Sign Monitoring Equipment Based on Flexible Electronic Devices in the Diagnosis and Treatment of Cardiovascular Diseases
NCT07466056Cardiovascular Disease
Beijing Anzhen Hospital
Observational
1,100
Beijing
2024-10-01
Recruiting
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
NCT06609863Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy
Sun Yat-sen University
Not applicable
27
Beijing
2024-10-01
Recruiting
Impact of Frequency-specific Subthalamic Nucleus Subregion Stimulation on Inhibitory Control in Parkinson's Disease
NCT07022522Parkinson Disease, Deep Brain Stimulation
Beijing Tiantan Hospital
Not applicable
20
Beijing
2024-10-01
Recruiting
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
NCT06471946Higher-risk Myelodysplastic Syndromes
DrugVenetoclax
Navy General Hospital, Beijing
Phase 1/2
54
Beijing
2024-10-01
Recruiting
HAIC Compared With TACE in Huge Hepatocellular Carcinoma
NCT06641713Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer
Sun Yat-sen University
Observational
664
Beijing
2024-10-01
Recruiting
Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma
NCT06624098Advanced Hepatocellular Carcinoma, Variceal Bleeding
Sun Yat-sen University
Not applicable
22
Beijing
2024-10-01
Not yet open
The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain
NCT06614608Osteoarthritis, Knee, Pain
DrugASKC200
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
24
Beijing
2024-10
Not yet open
A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia
NCT06670872Pneumonitis, Acinetobacter Baumannii
Peking University Third Hospital
Observational
50
Beijing
2024-10
Not yet open
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
NCT06601517Healthy Adult Subject, Overweight Subject
DrugsRepaglinide·HDM1002·Digoxin·Atorvastatin
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
30
Beijing
2024-10
Active, closed
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
NCT06464692Colorectal Cancer
DrugTelisotuzumab Adizutecan
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
DrugLunsekimig
Sanofi
Phase 2
900
Beijing, Changchun, Changsha, Chengde, Guangzhou, Guiyang, Hefei, Hohhot
2024-09-30
Recruiting
Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis
NCT06422845Arteriovenous Fistula Stenosis
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
328
Hefei, Beijing, Chongqing, Guanzhou, Huizhou, Shenzhen, Liuzhou, Nanning
2024-09-30
Recruiting
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
NCT06530303Colorectal Cancer, Colon Cancer, Rectum Cancer
DrugsTumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine·Cyclophosphamide
Essen Biotech
Phase 1/2
85
Beijing
2024-09-29
Recruiting
Bactiseal Catheter Safety Registry Study
NCT06276543Hydrocephalus
Integra LifeSciences Corporation
Observational
200
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu
2024-09-29
Recruiting
A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens
NCT06732505Neuroendocrine Neoplasm
Peking University Cancer Hospital & Institute
Phase 1
36
Beijing
2024-09-29
By invitation
โถโธGa-DPA in the Lung Cancer Diagnosis
NCT07023068Lung Cancers
Peking Union Medical College Hospital
Phase EARLY_PHASE1
40
Beijing
2024-09-28
Recruiting
Evaluation of the Effect of SURGICELยฎ Powder in TKA
NCT06608992Knee Osteoarthritis
Peking University Third Hospital
Phase 4
112
Beijing
2024-09-28
Recruiting
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
NCT06564272Ewing Sarcoma
DrugKC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2
30
Beijing
2024-09-27
By invitation
A Study to Evaluate the Safety and Efficacy of Staged Bilateral Magnetic Resonance-Guided Focused Ultrasound Thalamotomy for the Treatment of Essential Tremor
NCT06676501Essential Tremor, Essential Tremor, Movement Disorders
Chinese PLA General Hospital
Not applicable
20
Beijing
2024-09-26
Active, closed
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
NCT06635447Breast Cancer
DrugsCapivasertib·Fulvestrant
AstraZeneca
Phase 3
293
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Deyang
2024-09-26
Active, closed
A Study in Patients With Myasthenia Gravis in China
NCT06700616Myasthenia Gravis
AstraZeneca
Observational
1,199
Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan
2024-09-26
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Xi'an, Shanghai
2024-09-26
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
DrugLP352
Longboard Pharmaceuticals
Phase 3
96
Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi
2024-09-25
Recruiting
A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects
NCT06669429Dyslipidemia
Peking University First Hospital
Phase 1
72
Beijing
2024-09-25
Recruiting
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT06530251Hepatocellular Carcinoma
DrugsAK127·AK130·Bevacizumab biosimilar·Cadonilimab
Akeso
Phase 1/2
280
Beijing, Jinan
2024-09-24
Recruiting
Pola-ZR2P in Previously Untreated DLBCL
NCT06664411Diffuse Large B-cell Lymphoma
Navy General Hospital, Beijing
Phase 2
80
Beijing
2024-09-24
Recruiting
A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
NCT06776861Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
150
Beijing
2024-09-24
Active, closed
Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis
NCT06493279Amyotrophic Lateral Sclerosis Als
RJK Biopharma Ltd
Phase 1
9
Beijing
2024-09-24
Recruiting
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy๏ผˆRECAST-MT๏ผ‰
NCT06559241Acute Ischemic Stroke, Anterior Circulation Brain Infarction
Capital Medical University
Phase 3
2,105
Suzhou, Taihe Chengguanzhen, Tongling, Beijing, Fuzhou, Zhangzhou, Shenzhen, Nanning
2024-09-23
Not yet open
A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight
NCT06606483Obesity, Overweight and Obesity
DrugMDR-001
MindRank AI Ltd
Phase 2
300
Hefei, Xuancheng, Zibo, Beijing, Haikou, Shijiazhuang, Harbin, Luoyang
2024-09-23
Recruiting
The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
NCT06609447Ulcerative Colitis
DrugVedolizumab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xiโ€™an, Chengdu, Hangzhou, Huzhou
2024-09-21
Not yet open
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
NCT06470841Acute Myeloid Leukemia
Navy General Hospital, Beijing
Phase 2
85
Beijing
2024-09-20
Recruiting
Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis
NCT05860569Hypertriglyceridemia, Familial
GeneCradle Inc
Phase 1
7
Beijing
2024-09-20
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsLevoleucovorin·Patritumab Deruxtecan·Leucovorin·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-09-20
Recruiting
Hydration Guided by Remote Dielectric Sensing (ReDS) System for Preventing Acute Kidney Injury in Elderly Patients With Renal Insufficiency for Coronary Angiography and Intervention
NCT07394959Coronary Artery Disease, Chronic Kidney Disease, Elderly
Chinese PLA General Hospital
Not applicable
320
Beijing
2024-09-20
By invitation
Correlation Between Gut Microbiota and Pancreatic ฮ’-Cell Function in Diabetic Patients
NCT06645223Diabetes Mellitus, Gut Microbiota
Peking University Third Hospital
Observational
160
Beijing
2024-09-20
Not yet open
Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients
NCT06592625Untreated Early-stage or Locally Advanced Breast Cancer
DrugsTrastuzumab Rezetecan·Adebrelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
60
Beijing
2024-09-20
Recruiting
Safety and Efficacy Study of PUMCH-E101 Injection in Subjects with RDH12 Retinopathy
NCT06749639Inherited Retinal Diseases
Peking Union Medical College Hospital
Phase EARLY_PHASE1
10
Beijing
2024-09-20
Not yet open
To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection
NCT06561594Idiopathic Hypogonadotropic Hypogonadism
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
60
Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang
2024-09-20
Recruiting
Outcomes and Risk Factors of Different Treatment Strategies for Neuro-co-cardiological Diseases and Post-cardiac Surgery Cerebrovascular Diseases
NCT07012668Neuro-co-cardiological Diseases, Post-cardiac Surgery Cerebrovascular Diseases, Vascular Lesion
Beijing Anzhen Hospital
Observational
2,000
Beijing
2024-09-19
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
NCT06927466Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1
33
Beijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
2024-09-19
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148Geographic Atrophy, Macular Degeneration
Janssen Research & Development, LLC
Phase 2/3
274
Beijing, Chengdu, Shanghai
2024-09-19
Active, closed
A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation
NCT07406854Leber Hereditary Optic Neuropathy (LHON)
Wuhan Neurophth Biotechnology Limited Company
Phase 3
95
Beijing
2024-09-19
By invitation
Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors
NCT07182175Primary Aldosteronism, Adrenal Tumor, Cushing s Syndrome, Pheochromocytoma/Paraganglioma (PPGL)
Peking University First Hospital
Observational
150
Beijing
2024-09-19
Recruiting
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
NCT06554509Prurigo Nodularis
DrugSHR-1819
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2/3
423
Beijing
2024-09-19
Active, closed
A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
NCT06516302Chronic Rhinosinusitis With Nasal Polyps
DrugGR1802
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
228
Beijing
2024-09-19
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
Active, closed
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163Systemic Lupus Erythematosus
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
190
Hefei, Beijing, Guangzhou, Shenzhen, Shijiazhuang, Nanchang, Pudong, Shanghai
2024-09-17
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
400
Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou
2024-09-17
Active, closed
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
NCT06537999Multifocal Motor Neuropathy
DrugClaseprubart
Dianthus Therapeutics
Phase 2
46
Beijing, Shanghai
2024-09-17
Active, closed
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer
DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
Not yet open
Factors Affecting Selection of Leadless Pacemaker and Atrioventricular Synchronous Pacing Status
NCT06587672Pacemaker, Atrioventricular Block, Clinical Trials, Pacing
Xiaohan Fan
Observational
112
Beijing
2024-09-15
Recruiting
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
NCT06783114Upper Limb Spasticity
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 2/3
254
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Kaifeng, Wuhan, Huai'an
2024-09-14
Recruiting
Distribution of Mood and Personality Characteristics and Their Influence on Treatment Compliance
NCT07101796Personality, Patient Compliance, Anxiety, Depression
Peking University First Hospital
Observational
200
Beijing
2024-09-14
Recruiting
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
NCT06580574Gastric Cancer, Colon Cancer, MSI-H, DMMR Cancer
Peking University
Phase 2
34
Beijing
2024-09-13
Recruiting
Individualized Exploration of Aerobic Exercise-assisted Treatment of Depression
NCT06594588Depression - Major Depressive Disorder
Peking University
Not applicable
80
Beijing
2024-09-12
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Ivonescimab
Eli Lilly and Company
Phase 1
630
Beijing, Harbin, Shanghai
2024-09-12
Recruiting
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
DrugsPaclitaxel-albumin·Camrelizumab·Cisplatin
Tongji Hospital
Phase 2
40
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-09-12
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
DrugBelimumab
GlaxoSmithKline
Phase 3
440
Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai
2024-09-11
Active, closed
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
NCT06487559Hepatocellular Carcinoma (HCC)
AbbVie
Phase 1
3
Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang
2024-09-11
Recruiting
A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain
NCT06596681Pain, Intractable
Beijing Tiantan Hospital
Phase EARLY_PHASE1
6
Beijing
2024-09-11
Recruiting
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
NCT06596915Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma, Breast Cancer, Melanoma
Shandong Boan Biotechnology Co., Ltd
Phase 1
167
Beijing
2024-09-11
Recruiting
Outcomes for Anesthesiologist-Led Care of Analgesic Protocol in Anorectal Surgery
NCT06015165Postoperative Pain
China-Japan Friendship Hospital
Not applicable
216
Beijing
2024-09-10
Not yet open
Thermal Ablation Vs Thyroidectomy for Large Benign Thyroid Nodules
NCT06607133Benign Thyroid Nodules
Ming-an Yu
Observational
300
Beijing
2024-09-10
Recruiting
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
NCT06532799Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma, Esophageal Cancer
DrugsCyclophosphamid·Tumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine
Essen Biotech
Phase 1/2
75
Beijing
2024-09-10
Recruiting
Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.
NCT06771609Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
150
Beijing
2024-09-10
Recruiting
Postoperative Complications Following Skull Base Tumor Resection
NCT06587906Skull Base Tumor, Postoperative Complications
Beijing Tiantan Hospital
Observational
122
Beijing
2024-09-10
Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558Community-acquired Pneumonia
Shanghai SIMR Biotechnology Co., Ltd.
Phase 2
240
Fuyang, Beijing, Zhangzhou, Gaozhou, Guangzhou, Shantou, Yulin, Shijiazhuang
2024-09-10
Recruiting
Safety and Efficacy of RIC in Pediatric Moyamoya Disease Patients Treated With Revascularization Therapy
NCT03546309Moyamoya Disease, Pediatric
Capital Medical University
Not applicable
42
Beijing
2024-09-10
Recruiting
Basilar Artery Occlusion Chinese Endovascular Trial in the Extended Time Window
NCT06560203Acute Ischemic Stroke, Basilar Artery Occlusion
Capital Medical University
Not applicable
309
Beijing
2024-09-10
Recruiting
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
NCT06692166Cervical Cancer
Drug9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3
420
Beijing, Shanghai
2024-09-10
Recruiting
FAPI Imaging Assessment of Chronic Total Occlusion
NCT06655922Chronic Total Occlusion (CTO)
Lin Zhao
Observational
167
Beijing
2024-09-10
By invitation
Comparison of 6F and 7F Sheaths for Coronary Intervention Via Distal Radial Artery Access
NCT06585917PCI, Coronary Arterial Disease (CAD)
China National Center for Cardiovascular Diseases
Not applicable
574
Beijing
2024-09-10
Recruiting
Observation of Exhaled VOC Biomarkers Characteristics in Admitted Women with Breast Ultrasound BI-RADS 4 Grade
NCT06489158Breast Cancer
Peking Union Medical College Hospital
Observational
168
Beijing
2024-09-09
Recruiting
Online Adaptive Radiotherapy for Cervical Cancer
NCT06562166Cervical Cancer
Peking Union Medical College Hospital
Phase 2
124
Beijing
2024-09-05
Recruiting
ICAS Screen Based on RIC
NCT06610578Intracranial Atherosclerosis
Xuanwu Hospital, Beijing
Observational
2,100
Beijing
2024-09-05
Active, closed
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
2,099
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai
2024-09-04
Recruiting
Er:YAG Laser and Air Polishing Application in Periodontal Treatment
NCT06574802Periodontitis
Beijing Chao Yang Hospital
Not applicable
60
Beijing
2024-09-04
Recruiting
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
NCT06482905High-grade Glioma, WHO Grade โ…ฃ Glioma
Tcelltech Inc.
Phase 1
52
Beijing
2024-09-04
Recruiting
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
NCT06631989EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
DrugWSD0922-FU
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Recruiting
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
NCT06635798Tetanus
DrugHTIG
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
582
Hefei, Beijing, Guangzhou, Shenzhen, Liuzhou, Zunyi, Wuhan, Hengyang
2024-09-03
Recruiting
A RWS of SC MTX in Chinese RA Patients
NCT07463937Rheumatoid Arthritis (RA)
Peking University People's Hospital
Observational
10,000
Beijing
2024-09-03
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795Solid Tumor, Adult
DualityBio Inc.
Phase 1/2
360
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Nanning, Harbin, Luoyang
2024-09-03
Recruiting
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
NCT06512584Short Bowel Syndrome
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 3
72
Beijing, Chongqing, Guangzhou, Changsha, Nanjing, Qingdao, Shanghai, Xiโ€™an
2024-09-03
Recruiting
Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
NCT06477536Generalized Pustular Psoriasis
DrugHB0034
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 2/3
33
Beijing, Hangzhou
2024-09-02
Recruiting
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
NCT06736275Advanced Cancer, Cachexia
Jiangsu Nutai Biologics Co., Ltd
Phase EARLY_PHASE1
28
Beijing
2024-09-02
Recruiting
Treatment of ACuTe Coronary Syndromes With Low-dose colchICine
NCT06215989Acute Coronary Syndrome, Unstable Angina, ST Elevation Myocardial Infarction, Non ST Segment Elevation Myocardial Infarction
DrugColchicine Pill
Beijing Anzhen Hospital
Not applicable
6,574
Beijing
2024-09-02
Recruiting
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
NCT06549855Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency
DrugSintilimab
Peking University People's Hospital
Not applicable
10
Beijing
2024-09-02
Rows per page Showing 3101–3200 of 5484
Previous 30 31 32 33 34 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=32

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.